Evidence map›Paper›PMID 26340618›Full record

ReviewInternational journal of molecular sciences2015

Mitochondria: A Therapeutic Target for Parkinson's Disease?

Yu Luo, Alan Hoffer, Barry Hoffer, Xin Qi

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers.

0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed
10.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

63 citing papers in PubMed, 104 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Novel and experimental therapeutics for the management of motor and non-motor Parkinsonian symptoms.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024
    Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Atypical Ubiquitination and Parkinson's Disease.International journal of molecular sciences · 2022
    Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Mitochondrial Dysregulation and the Influence in Neurodegenerative Diseases.Advances in experimental medicine and biology · 2022
    Article

3 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Yu LuoDepartment of Neurological Surgery, Case Western Reserve University, Cleveland, OH 44106, USA. yxl710@case.edu.
Alan HofferDepartment of Neurological Surgery, Case Western Reserve University, Cleveland, OH 44106, USA. Alan.Hoffer@uhhospitals.org.
Barry HofferDepartment of Neurological Surgery, Case Western Reserve University, Cleveland, OH 44106, USA. bhoffer@intra.nida.nih.gov.
Xin QiDepartment of Physiology, Case Western Reserve University, Cleveland, OH 44106, USA. xxq38@case.edu.
Neurological Surgery · USCase Western Reserve University · US

Funding

Dynamin-related protein 1, neurodegeneration and Huntington's diseaseR01NS088192 · NINDS · CASE WESTERN RESERVE UNIVERSITY · PI QI, XIN · 2014 to 2018
$1.7M
NINDS NIH HHS R01 NS088192
6 · The paper itself

Abstract

Parkinson's disease (PD) is one of the most common neurodegenerative disorders. The exact causes of neuronal damage are unknown, but mounting evidence indicates that mitochondrial-mediated pathways contribute to the underlying mechanisms of dopaminergic neuronal cell death both in PD patients and in PD animal models. Mitochondria are organized in a highly dynamic tubular network that is continuously reshaped by opposing processes of fusion and fission. Defects in either fusion or fission, leading to mitochondrial fragmentation, limit mitochondrial motility, decrease energy production and increase oxidative stress, thereby promoting cell dysfunction and death. Thus, the regulation of mitochondrial dynamics processes, such as fusion, fission and mitophagy, represents important mechanisms controlling neuronal cell fate. In this review, we summarize some of the recent evidence supporting that impairment of mitochondrial dynamics, mitophagy and mitochondrial import occurs in cellular and animal PD models and disruption of these processes is a contributing mechanism to cell death in dopaminergic neurons. We also summarize mitochondria-targeting therapeutics in models of PD, proposing that modulation of mitochondrial impairment might be beneficial for drug development toward treatment of PD.

Indexed as

AnimalsAutophagyDNA, MitochondrialGenetic Association StudiesGenetic Predisposition to DiseaseHumansMitochondriaMitochondrial DynamicsMitochondrial ProteinsMitophagyMolecular Targeted TherapyMutationOxidation-ReductionParkinson DiseaseProtein TransportSignal TransductionDNA, MitochondrialMitochondrial ProteinsToxins, Biologicalmitochondrial dynamicsmitochondrial dysfunctionParkinson’s disease

Identifiers

PMID26340618
PMCPMC4613227
OpenAlexW2138747394

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.